THE CAMBRIDGE INNOVATION PROGRAMME –

ADVANCED PRACTICES AND CASE STUDIES OF INNOVATION FOR SUCCESS

22 – 27 September 2019

VISITS* The Cambridge Biomedical Campus (https://cambridge-biomedical.com/the-campus) The Cambridge Biomedical Campus (CBC) is located at the heart of the UK’s and Europe’s leading life sciences cluster. They are a vibrant, international healthcare community and a global leader in medical science, research, education and patient care. By locating world-leading academic and industry scientists on the same site as the teaching hospitals of the , they are creating the optimum environment for the rapid and effective translation of research into routine clinical practice.

The Campus succeeds because of the strength of their ecosystem which allows ideas to develop and flourish. It fosters an environment where where like-minded people work in partnership, committed to realising a shared ambition of improving patient care and outcomes – through the discovery, commercialisation and adoption of innovative new products and services into healthcare practice.

Researchers can enjoy access to a comprehensive range of scientific support services and technology platforms often housed in dedicated core facilities and managed by highly qualified staff. In some cases, researchers are involved in the development of bespoke technologies. Scientists on the Campus also have access to a wide range of ethically obtained, well-characterised tissue and other samples including the Cambridge BioResource – a panel of around 16,000 volunteers, both with and without health conditions, who are willing to participate in research studies investigating the links between genes, the environment, health and disease.

Cambridge Design Partnership (https://www.cambridge-design.com) Established for 20 years, Cambridge Design Partnership is an independent innovation partner who has completed over 1,000 product development assignments for business around the world. Members of their team are named inventors on many hundreds of patents owned by their customers. They grow year on year, constantly expanding their experienced team and state of the art facilities. They are based in two of the world’s leading centres for science and technology. Their European office is in Cambridge UK, a city with an 800 year history in science and creative thinking. Their USA office is in Silicon Valley, probably the world’s most successful innovation hub.

Eagle (https://www.eaglegenomics.com) Eagle Genomics was founded in 2008 in response to the opportunities in translational genomics, enabled by next generation sequencing and cloud computing. Based at the world renowned Wellcome Genome Campus, the company has made tangible contributions to the field of genomics data analysis and has contributed first-hand to its evolution from basic research to a key driver of precision medicine. Their award winning smart data management platform allows scientists and other users to bridge the gap between data and new insights in a rapid, systematic and traceable way. Eagle Genomics has gained its position of leadership from engagements with leading life science R&D companies and partnerships with academic and non-profit organisations, as well as a range of blue chip clients in the healthcare, personal care and agritech sectors, enabling them to deliver game changing products and technologies into their respective markets.

1 | P a g e

Wellcome Genome Campus (https://www.wellcomegenomecampus.org) At the time of its official opening by the Princess Royal in 1994, the Wellcome Genome Campus was already home to the Sanger Institute (then called the Sanger Centre), the Medical Research Council’s Human Genome Mapping Project Resource Centre and the European Molecular Laboratory’s European Institute (EMBL-EBI). Wellcome funded the establishment of the Sanger Centre in 1993 and chose Hinxton as the home for its new genome research institute. Shortly after, EMBL-EBI also moved to the same site. The two institutes formed a natural fit, consolidating expertise, facilities and knowledge in one place and enabling both to contribute a major role in the - a global collaboration to sequence the first ‘reference’ human genome. One third of the human genome was sequenced for the first time at the Wellcome Trust Sanger Institute, and the precious data was stored and shared through EMBL-EBI. This was the largest single contribution of any centre to the Human Genome Project, making the Campus and its collaborations uniquely important in the history of genomics. Under the auspices of its owner, GRL Genome Research Limited, the Campus has grown to include several internationally-recognised organisations, such as Connecting Science and the BioData Innovation Centre. At its opening in 1994, the Campus housed approximately 400 employees. This has grown to over 2,600 people employed at the Wellcome Genome Campus today, making the Campus a densely concentrated and globally significant cluster for biodata and genomics expertise.

*The Visits List is subject to changes.

Updated on 2 August 2019

2 | P a g e